StocksCoherus Biosciences IncCHRS

CHRS

Coherus Biosciences Inc

13.73 1.09 (8.62%)
Delayed Prices By NASDAQ, in USD Market Closed
Trade
S
13.72
B
13.77

Overview

Prev Close13.73
Day's Range 12.65 - 13.92
52 Week Range 5.60 - 19.25
Average Volume (3m)1.13M
1-Year Return-1.45%
Beta1.1147
Market Cap1.07B
P/E Ratio9
Revenue276.14M
EPS-2.9732
Dividend (Yield)0 (0%)
1 Day 1 Week 1 Month 3 Months 6 Months 1 Year 3 Years Max
Created with Highcharts 4.2.7 /Highstock 4.2.703/03/202213/05/202226/07/20226.008.0010.0012.0014.00
Chart times in UTC
Industry Pharmaceuticals Major
CEO Denny M. Lanfear, MBA
Employees 332

FINANCIAL SUMMARY

For the fiscal year ended 31/12/2021: Coherus Biosciences Inc's revenues decreased by 31.37% and amounted to 326.55M. Net income decreased by 317.10% to -287.10M. Net assets decreased by 65.22% to 97.73M and EPS decreased from 1.62 to -3.81.
CHRS's Investor Relations
Income StatementBalance SheetCash Flow Statement
Quarterly
Gross Margin
79.80%
Net Profit Margin
-3,068.29%
Operating Margin
-71.44%
Return On Investment
-101.88%
09/21
12/21
03/22
06/22
Total Revenue
82.5M
73.37M
60.12M
60.15M
Gross Profit
61.22M
61.27M
50.75M
48.87M
Operating Income
-32.79M
-39.55M
-80.93M
-44.01M
Net Income
-38.53M
-45.73M
-96.08M
-50.15M